Terra Alpha Investments LLC Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

Terra Alpha Investments LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,580 shares of the medical research company's stock, valued at approximately $1,598,000. Edwards Lifesciences comprises 1.6% of Terra Alpha Investments LLC's holdings, making the stock its 24th largest holding.

Several other hedge funds have also recently modified their holdings of EW. Abacus Planning Group Inc. increased its holdings in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after acquiring an additional 140 shares during the last quarter. Bowman & Co S.C. increased its holdings in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after purchasing an additional 148 shares during the last quarter. Moors & Cabot Inc. lifted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after buying an additional 152 shares in the last quarter. Pegasus Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after buying an additional 159 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its holdings in Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock valued at $634,000 after buying an additional 162 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EW has been the subject of a number of research reports. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Down 0.7 %

Shares of NYSE:EW traded down $0.50 during trading hours on Friday, hitting $70.46. The company's stock had a trading volume of 7,144,270 shares, compared to its average volume of 4,605,777. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm's fifty day moving average price is $71.48 and its 200 day moving average price is $70.35. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $41.42 billion, a price-to-earnings ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.